



# Supplementary Data

## Supplementary Figure 1. Estimation of la/mUC cases in Mexico in year 1



# Supplementary Data

## Supplementary Figure 2. Acquisition costs of medication in the first year of treatment per treated patient in the cost-of-care model (MXN \$)



Costs were calculated by multiplying the monthly acquisition cost by the median treatment duration reported in the respective clinical trials. For avelumab maintenance: CT, 3.7 months; avelumab, 5.8 months. For EV + PEM: EV, 7.0 months; PEM, 8.5 months. For NIV + CT: NIV, 7.4 months; CT, 4.1 months.

**Ave**, avelumab; **BSC**, best supportive care; **CT**, platinum-based chemotherapy; **EV**, enfortumab vedotin; **NIV**, nivolumab; **PEM**, pembrolizumab.

# Supplementary Data

## Supplementary Table 1. Subsequent treatment

	CT → BSC <sup>2</sup>	CT → ave + BSC <sup>2</sup>	EV + PEM <sup>3</sup>	NIV + CT <sup>4</sup>
Patients receiving subsequent treatment, %	72.0	52.9	29.0	35.5

# Supplementary Data

## Supplementary Table 2. Estimated patient numbers by scenario

	Current scenario					Revised scenario				
	Year 1	Year 2	Year 3	Year 4	Year 5	Year 1	Year 2	Year 3	Year 4	Year 5
<b>Total</b>	539	543	547	552	556	539	543	547	552	556
<b>Scenario 1: EV + PEM</b>										
<b>EV + PEM</b>	0	0	0	0	0	377	435	438	441	445
<b>NIV + CT</b>	0	0	0	0	0	81	54	55	55	56
<b>CT → ave + BSC</b>	539	543	547	552	556	81	54	55	55	56
<b>Scenario 2: NIV + CT</b>										
<b>EV + PEM</b>	0	0	0	0	0	38	43	49	55	61
<b>NIV + CT</b>	0	0	0	0	0	178	228	279	331	384
<b>CT → ave + BSC</b>	539	543	547	552	556	323	272	219	165	111
<b>Scenario 3: CT → ave + BSC</b>										
<b>EV + PEM</b>	0	0	0	0	0	38	33	27	28	28
<b>NIV + CT</b>	0	0	0	0	0	38	33	27	28	28
<b>CT → ave + BSC</b>	539	543	547	552	556	464	478	493	496	500

Patient estimates were derived using available epidemiological and market share evidence and were validated with clinical experts. Patient estimates for year 1 are shown in Supplementary Figure 1. For subsequent years, the base population was adjusted according to the population growth rate (0.78%).

The estimated cumulative patient population over 5 years was 2,737 patients.

**Ave**, avelumab; **BSC**, best supportive care; **CT**, platinum-based chemotherapy; **EV**, enfortumab vedotin; **NIV**, nivolumab; **PEM**, pembrolizumab.

# Supplementary Data

## Supplementary references

1. GLOBOCAN. Cancer Today. Accessed March 12, 2026. <https://gco.iarc.fr/today/en>
2. Powles T, et al. *J Clin Oncol*. 2023;41(19):3486-92.
3. Powles T, et al. *N Engl J Med*. 2024;390(10):875-88.
4. van der Heijden MS, et al. *N Engl J Med*. 2023;389(19):1778-89.